357 related articles for article (PubMed ID: 22050756)
1. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.
Beierlein JM; Anderson AC
Curr Med Chem; 2011; 18(33):5083-94. PubMed ID: 22050756
[TBL] [Abstract][Full Text] [Related]
2. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
[TBL] [Abstract][Full Text] [Related]
3. Identification of Therapeutically Active Molecules against Anthrax through Structure and Ligand based Drug Design.
Nandi S; Saxena M; Saxena AK
Curr Top Med Chem; 2018; 18(27):2294-2312. PubMed ID: 30582475
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor.
Schein CH; Chen D; Ma L; Kanalas JJ; Gao J; Jimenez ME; Sower LE; Walter MA; Gilbertson SR; Peterson JW
Toxins (Basel); 2012 Nov; 4(11):1288-300. PubMed ID: 23202316
[TBL] [Abstract][Full Text] [Related]
5. Alternative pre-approved and novel therapies for the treatment of anthrax.
Head BM; Rubinstein E; Meyers AF
BMC Infect Dis; 2016 Nov; 16(1):621. PubMed ID: 27809794
[TBL] [Abstract][Full Text] [Related]
6. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
Zhu PJ; Hobson JP; Southall N; Qiu C; Thomas CJ; Lu J; Inglese J; Zheng W; Leppla SH; Bugge TH; Austin CP; Liu S
Bioorg Med Chem; 2009 Jul; 17(14):5139-45. PubMed ID: 19540764
[TBL] [Abstract][Full Text] [Related]
7. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
8. Recent Developments in Anti-dotes Against Anthrax.
Dhasmana N; Singh LK; Bhaduri A; Misra R; Singh Y
Recent Pat Antiinfect Drug Discov; 2014; 9(2):83-96. PubMed ID: 25174439
[TBL] [Abstract][Full Text] [Related]
9. New insights into the pathogenesis and treatment of anthrax toxin-induced shock.
Li Y; Sherer K; Cui X; Eichacker PQ
Expert Opin Biol Ther; 2007 Jun; 7(6):843-54. PubMed ID: 17555370
[TBL] [Abstract][Full Text] [Related]
10. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.
Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW
Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734
[TBL] [Abstract][Full Text] [Related]
11. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
[No Abstract] [Full Text] [Related]
12. Dr. Jekyll and Mr. Hyde: a short history of anthrax.
Schwartz M
Mol Aspects Med; 2009 Dec; 30(6):347-55. PubMed ID: 19577591
[TBL] [Abstract][Full Text] [Related]
13. Peptide inhibitors MAP the way towards fighting anthrax pathogenesis.
DeCathelineau AM; Bokoch GM
Biochem J; 2006 Apr; 395(1):e1-3. PubMed ID: 16541485
[TBL] [Abstract][Full Text] [Related]
14. Past, imminent and future human medical countermeasures for anthrax.
Baillie LW
J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
[TBL] [Abstract][Full Text] [Related]
15. Anthrax vaccines: Pasteur to the present.
Scorpio A; Blank TE; Day WA; Chabot DJ
Cell Mol Life Sci; 2006 Oct; 63(19-20):2237-48. PubMed ID: 16964578
[TBL] [Abstract][Full Text] [Related]
16. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W
BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
[TBL] [Abstract][Full Text] [Related]
18. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
Bouzianas DG
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429
[TBL] [Abstract][Full Text] [Related]
19. Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.
Mamedov T; Chichester JA; Jones RM; Ghosh A; Coffin MV; Herschbach K; Prokhnevsky AI; Streatfield SJ; Yusibov V
PLoS One; 2016; 11(4):e0153956. PubMed ID: 27101370
[TBL] [Abstract][Full Text] [Related]
20. Progress and novel strategies in vaccine development and treatment of anthrax.
Chitlaru T; Altboum Z; Reuveny S; Shafferman A
Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
